IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered into an agreement to acquire all the assets of Radcal Corporation (Monrovia, CA, USA), a leader in diagnostic X-ray measurement. With the acquisition of Radcal, IBA will further strengthen its Medical Imaging Quality Assurance offering as well as its presence in the US market.

Radcal, a pioneer in the X-ray imaging market, introduced the first instrument to provide comprehensive measures of X-ray dose with the capability to interchange sensors without any loss in accuracy, almost 50 years ago. The integration of Radcal into IBA’s business will aid its continued growth in the dosimetry and quality assurance field, further strengthening its foothold in the key US market and expanding its product offering beyond OEM and into the clinical setting.

“This acquisition strengthens our position as a global leader in Medical Imaging Dosimetry and Quality Assurance, complementing our leading position in the radiotherapy market and diversifying our revenue sources,” said Olivier Legrain, Chief Executive Officer at IBA. “We see tremendous potential for the combined business both in the US and the international market and look forward to working closely with the Radcal team to continue the strong growth of its leading offering.”

“We are delighted to welcome the talented and dedicated Radcal team to IBA group,” added Jean-Marc Bothy, President of IBA Dosimetry. “We are committed to providing the very best in medical imaging and radiotherapy quality assurance to our customers globally, contributing to our ultimate goal to treat more patients safely. Radcal’s growing product offering will enable us to reach new customers in the US and expand our presence in the Medical Imaging Quality Assurance market internationally.”

Related Links:
IBA
Radcal Corporation